Helping HCPs navigate the ever-evolving advanced cancer landscape
OPEN Health’s Christine Drewienkiewicz, Sara Black and Annie Rankin on advances in modern oncology and how pharma can help ensure maximum patient benefit
Every year, the American Society of Clinical Oncology (ASCO) shares the latest potentially practice-changing research at its annual meeting and, despite the COVID-19 pandemic, this year was no exception. Cancelling the most important congress in the oncology calendar was not an option so, for the first time in its 55-year history, ASCO went fully virtual in 2020.
This presented an opportunity to rethink how pharma, researchers, healthcare professionals and patients communicate, to enable all stakeholders to keep up with developments – particularly important in an era when each new development can help change at least some types of advanced cancer from a lethal to a more chronic disease.
• Read the full article in pharmaphorum’s Deep Dive digital magazine